侵袭性真菌感染的挑战[精品文档].pptVIP

下载本文档

2
0
约2.13万字
约 120页
2018-03-06 发布于江西
举报
版权申诉

侵袭性真菌感染的挑战[精品文档].ppt

1、原创力文档（book118）网站文档一经付费（服务费），不意味着购买了该文档的版权，仅供个人/单位学习、研究之用，不得用于商业用途，未经授权，严禁复制、发行、汇编、翻译或者网络传播等，侵权必究。。
2、本站所有内容均由合作方或网友上传，本站不对文档的完整性、权威性及其观点立场正确性做任何保证或承诺！文档内容仅供研究参考，付费前请自行鉴别。如您付费，意味着您自己接受本站规则且自行承担风险，本站不退款、不进行额外附加服务；查看《如何避免下载的几个坑》。如果您已付费下载过本站文档，您可以点击这里二次下载。
3、如文档侵犯商业秘密、侵犯著作权、侵犯人身权等，请点击“版权申诉”（推荐），也可以打举报电话：400-050-0827(电话支持时间：9:00-18:30)。
4、该文档为VIP文档，如果想要下载，成为VIP会员后，下载免费。
5、成为VIP后，下载本文档将扣除1次下载权益。下载后，不支持退款、换文档。如有疑问请联系我们。
6、成为VIP后，您将拥有八大权益，权益包括：VIP文档下载权益、阅读免打扰、文档格式转换、高级专利检索、专属身份标志、高级客服、多端互通、版权登记。
7、VIP文档为合作方或网友上传，每下载1次，网站将根据用户上传文档的质量评分、类型等，对文档贡献者给予高额补贴、流量扶持。如果你也想贡献VIP文档。上传文档

侵袭性真菌感染的挑战[精品文档]

* * * * * * * * Studies in vitro show that caspofungin is not an inhibitor of any enzyme in the cytochrome P-450 (CYP) system. In clinical studies, caspofungin did not induce the CYP3A4 metabolism of other drugs. Caspofungin is not a substrate for P-glycoprotein and is a poor substrate for CYP-450 enzymes.18 Concomitant use with cyclosporine is not recommended unless the potential benefit outweighs the potential risk to the patient.18 In one clinical study, three of four subjects who received caspofungin 70 mg on days 1 through 10 and cyclosporine (two 3 mg/kg doses administered 12 hours apart on day 10) developed transient elevations of alanine transaminase (ALT) on day 11 that were two to three times the upper limit of normal (ULN).18 In a separate panel of subjects within the same study, two of eight patients who received caspofungin 35 mg daily for 3 days and cyclosporine (two 3 mg/kg doses administered 12 hours apart on day 1) had smaller increases in ALT (slightly above the ULN) on day 2.18 In both groups, elevations in aspartate transaminase (AST) paralleled ALT elevations, but were of lesser magnitude.18 * Use Av conc SS * QC K Dejonghe (17 Sep 2001) - No QC issues. * QC’d by Scott Vincent on 19/06/2001 QC Issues: 10000001057162\5.0\Approved\18-Oct-2000 10:13 10000001065376\10.17\Approved\26-Oct-2000 12:45 10000001041465\4.0\Approved\04-Oct-2000 12:22 10000000830606\3.9\Approved\06-Mar-2000 08:12 10000000848784\1.3\Approved\07-Sep-2000 11:36 10000001044066\4.3\Approved\06-Oct-2000 09:46 10000001178822\4.3\Approved\27-Mar-2001 04:17 * QC’d by Scott Vincent on 19/06/2001 QC Issues: 10000001057162\5.0\Approved\18-Oct-2000 10:13 10000001065376\10.17\Approved\26-Oct-2000 12:45 10000001041465\4.0\Approved\04-Oct-2000 12:22 10000000830606\3.9\Approved\06-Mar-2000 08:12 10000000848784\1.3\Approved\07-Sep-2000 11:36 10000001044066\4.3\Approved\06-Oct-2000 09:46 10000001178822\4.3\Approved\27-Mar-2001 04:17 * * QC K Dejonghe (17 Sep 2001) - No QC issu